Skip Nav Destination

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4

J Exp Med (2013) 210 (7): 1389–1402.
Currently there are no citedby results. Try again later.